I'm not referring to either of them having access to the double blinded results, rather I think they had enough in house testing/knowledge that they were likely to suspect that Lucentis might perform significantly better. I would suspect that lucentis was designed to overcome some of the issues that were identified in Avastin.
Market Data 
Markets 
AI
